| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:1592.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Departments of Radiology and Cardiology, University Hospital Groningen (D.K., K.Y.J.A.M.H., R.V., M.O.); Bronovo Hospital, The Hague (D.K., P.R.M.v.D.), the Netherlands; and the Department of Cardiology, Leiden University Medical Center (P.R.M.v.D.), Leiden, the Netherlands.
Correspondence to Dirkjan Kuijpers, MD, Department of Radiology, University Hospital Groningen, Hanzeplein 1, 9713GZ Groningen, The Netherlands. E-mail kps{at}xs4all.nl
Background The purpose of this study was to assess the value of high-dose dobutamine cardiovascular magnetic resonance (CMR) with myocardial tagging for the detection of wall motion abnormalities as a measure of myocardial ischemia in patients with known or suspected coronary artery disease.
Methods and Results Two hundred eleven consecutive patients with chest pain underwent dobutamine-CMR 4 days after antianginal medication was stopped. Dobutamine-CMR was performed at rest and during increasing doses of dobutamine. Cine-images were acquired during breath-hold with and without myocardial tagging at 3 short-axis levels. Regional wall motion was assessed in a 16-segment short-axis model. Patients with new wall motion abnormalities (NWMA) were examined by coronary angiography. Dobutamine-CMR was successfully performed in 194 patients. Dobutamine-CMR without tagging detected NWMA in 58 patients, whereas NWMA were detected in 68 patients with tagging (P=0.002, McNemar). Coronary angiography showed coronary artery disease in 65 (96%) of these 68 patients. All but 3 of the 65 patients needed revascularization. In the 112 patients with a negative dobutamine-CMR study, without baseline wall motion abnormalities, the cardiovascular occurrence-free survival rate was 98.2% during the mean follow-up period of 17.3 months (range, 7 to 31).
Conclusions Dobutamine-CMR with myocardial tagging detected more NWMA compared with dobutamine-CMR without tagging and reliably separated patients with a normal life expectancy from those at increased risk of major adverse cardiac events.
Key Words: magnetic resonance imaging myocardium stress ischemia
This article has been cited by other articles:
![]() |
G. Korosoglou, D. Lossnitzer, D. Schellberg, A. Lewien, A. Wochele, T. Schaeufele, M. Neizel, H. Steen, E. Giannitsis, H. A. Katus, et al. Strain-Encoded Cardiac MRI as an Adjunct for Dobutamine Stress Testing: Incremental Value to Conventional Wall Motion Analysis Circ Cardiovasc Imaging, March 1, 2009; 2(2): 132 - 140. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Potter, P. A. Araoz, K. P. McGee, W. S. Harmsen, J. N. Mandrekar, and T. M. Sundt III Low-dose dobutamine cardiac magnetic resonance imaging with myocardial strain analysis predicts myocardial recoverability after coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg., June 1, 2008; 135(6): 1342 - 1347. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J.W. Gotte, T. Germans, I. K. Russel, J. J.M. Zwanenburg, J. T. Marcus, A. C. van Rossum, and D. J. van Veldhuisen Myocardial Strain and Torsion Quantified by Cardiovascular Magnetic Resonance Tissue Tagging: Studies in Normal and Impaired Left Ventricular Function J. Am. Coll. Cardiol., November 21, 2006; 48(10): 2002 - 2011. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu, L. Sun, Y. Huan, H. Zhao, and J. Deng Effects of basic fibroblast growth factor microspheres on angiogenesis in ischemic myocardium and cardiac function: analysis with dobutamine cardiovascular magnetic resonance tagging. Eur. J. Cardiothorac. Surg., July 1, 2006; 30(1): 103 - 107. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Paetsch, C. Jahnke, V. A. Ferrari, F. E. Rademakers, P. A. Pellikka, W. G. Hundley, D. Poldermans, J. J. Bax, K. Wegscheider, E. Fleck, et al. Determination of interobserver variability for identifying inducible left ventricular wall motion abnormalities during dobutamine stress magnetic resonance imaging Eur. Heart J., June 2, 2006; 27(12): 1459 - 1464. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Paetsch, C. Jahnke, E. Fleck, and E. Nagel Current clinical applications of stress wall motion analysis with cardiac magnetic resonance imaging Eur J Echocardiogr, October 1, 2005; 6(5): 317 - 326. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Paetsch, D. Foll, A. Kaluza, R. Luechinger, M. Stuber, A. Bornstedt, A. Wahl, E. Fleck, and E. Nagel Magnetic resonance stress tagging in ischemic heart disease Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2708 - H2714. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Pennell, U. P. Sechtem, C. B. Higgins, W. J. Manning, G. M. Pohost, F. E. Rademakers, A. C. van Rossum, L. J. Shaw, and E. K. Yucel Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report Eur. Heart J., November 1, 2004; 25(21): 1940 - 1965. [Full Text] [PDF] |
||||
![]() |
A. Wahl, I. Paetsch, S. Roethemeyer, C. Klein, E. Fleck, and E. Nagel High-Dose Dobutamine-Atropine Stress Cardiovascular MR Imaging after Coronary Revascularization in Patients with Wall Motion Abnormalities at Rest Radiology, October 1, 2004; 233(1): 210 - 216. [Abstract] [Full Text] [PDF] |
||||
![]() |
Jérôm. Garot The study of diastole by tagged MRI: are we nearly there yet? Eur. Heart J., August 2, 2004; 25(16): 1376 - 1377. [Full Text] [PDF] |
||||
![]() |
H. S. Maniar, B. P. Cupps, D. D. Potter, P. Moustakidis, C. J. Camillo, C. M. Chu, M. K. Pasque, and T. M. Sundt III Ventricular function after coronary artery bypass grafting: Evaluation by magnetic resonance imaging and myocardial strain analysis J. Thorac. Cardiovasc. Surg., July 1, 2004; 128(1): 76 - 82. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |